Pacific Biosciences of California Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (32)

Latest Posts

About This Stock More About This Stock
Pacific Biosciences Upgraded To Overweight From Neutral At Piper Jaffray
Article By: The Fly
Tuesday, October 15, 2019 7:33 AM EDT
Piper Jaffray analyst William Quirk upgraded Pacific Biosciences of California to Overweight from Neutral with an unchanged price target of $8.
In this article: PACB Also: ILMN
Merger Arbitrage Spread Performance - Feb. 24, 2019
Article By: Mal Spink
Sunday, February 24, 2019 2:18 PM EDT
This is the analysis and performance review of the top 20 US based cash merger arbitrage spreads for the week 19th-22nd February. Included in this week's report are the winners, losers and overall performance of the portfolio.
In this article: NXTM, RHT, TRCO, NXST, PACB, MNA, SPY, HIFR
Illumina To Acquire Pacific Biosciences For $8 Per Share
Article By: The Fly
Thursday, November 1, 2018 5:15 PM EDT
The agreement has been approved by the board of directors of Illumina and Pacific Biosciences. The acquisition complements Illumina sequencing solutions with accurate long-read sequencing capabilities to answer a set of complex genomic questions.
In this article: ILMN, PACB
Pacific Biosciences Of California, Inc. Announces Proposed Public Offering Of Common Stock
Article By: NASDAQ GlobeNewswire
Monday, February 12, 2018 5:44 PM EDT
Pacific Biosciences of California, Inc. today announced that it intends to offer and sell shares of its common stock in an underwritten public offering.
In this article: PACB
Pacific Biosciences Looks Promising As It Targets Low Competition Plant Genome Segment
Article By: KKD Healthcare Analytics
Thursday, June 29, 2017 9:51 AM EDT
Pacific Biosciences has taken several remedial steps to ensure that Sequel systems gain wider approval in the market. These steps included designing software and chemical updates for the systems.
In this article: PACB


Latest Tweets for $PACB

No tweets yet!